As the Association representing the European biotechnology industry, EuropaBio is fully committed to the development of a legislative environment which facilitates the creation of EU jobs and growth as well as new solutions to healthcare challenges.
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies